NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

Core Insights - NorthStrive Biosciences, a subsidiary of PMGC Holdings, has provided an update on the timeline for Phase III of its AI Development Program in collaboration with Yuva Biosciences, with results expected in Q2 2026 [1][3] Group 1: Company Updates - NorthStrive Biosciences initiated Phase III of its AI Development Program on December 17, 2025, which is anticipated to last approximately 6 to 9 weeks [1] - Yuva Biosciences has developed improved sixth-generation classifier models that enhance screening accuracy and sensitivity, which will be utilized in the Phase III study [2] - The extended timeline for Phase III results is expected to yield more robust and reliable outcomes to support further development efforts [3] Group 2: Company Background - Yuva Biosciences specializes in mitochondrial sciences and employs advanced AI to identify therapeutic candidates targeting aging-related pathways, with its proprietary platform MitoNova™ [4] - NorthStrive Biosciences focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at addressing obesity while preserving muscle during weight loss treatments [5] - PMGC Holdings is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [6]